Last reviewed · How we verify

NPO Petrovax — Portfolio Competitive Intelligence Brief

NPO Petrovax pipeline: 1 marketed, 0 filed, 2 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 4 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Longidaza® Longidaza® marketed
Grippol Quadrivalent Grippol Quadrivalent phase 3 Inactivated influenza vaccine Immunology / Infectious Disease
Grippol Plus Grippol Plus phase 3 Inactivated influenza vaccine Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
  2. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  3. Brigham and Women's Hospital · 1 shared drug class
  4. Chiltern Pesquisa Clinica Ltda · 1 shared drug class
  5. Fluart Innovative Vaccine Ltd, Hungary · 1 shared drug class
  6. Folia Biotech Inc. · 1 shared drug class
  7. GlaxoSmithKline · 1 shared drug class
  8. Ab&B Bio-tech Co., Ltd.JS · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for NPO Petrovax:

Cite this brief

Drug Landscape (2026). NPO Petrovax — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/npo-petrovax. Accessed 2026-05-16.

Related